Boston Therapeutics Inc (OTC:BTHE)

Friday, August 9, 2013 | Web News
Second Quarter 2013 Results Revenue for the second quarter was $2,118, compared with $2,376 in the prior year's quarter....
Wednesday, October 10, 2012 | Web News
Investor presentation via 8k filed on 10/10/2012
Wednesday, April 18, 2012 | Web News
MANCHESTER, NH--(Marketwire - Apr 18, 2012) - Boston Therapeutics, Inc. (OTCBB: BTHE), a developer of diabetes...
See All Research...
Boston Therapeutics, Inc., a development stage company, engages in the development, manufacture, and commercialization of therapeutic drugs and dietary supplements for human health. It focuses on glyco-pathology. The company offers PAZ-320, an oral drug candidate for diabetes; and SUGARDOWN, a complex carbohydrate-based dietary supplement. It is also developing IPOXYN, an anti-hypoxia drug. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is based in Manchester, New Hampshire.

Web site: http://www.bostonti.com

Last updated April 17, 2012


Market Data powered by QuoteMedia. Terms of Use